Neilawattie Merna Timaul

Dedicated research scientist, laboratory manager, and wellness consultant with expertise in laboratory research and administration. Collaborative leader known for aligning teams with organizational objectives and driving performance. Skilled at navigating complex challenges, fostering innovation, and ensuring adaptability to evolving market conditions. Experienced in strategic planning, operational excellence, multitasking, and managing laboratory operations efficiently. Proficient in molecular and cellular biology, biochemistry, virology, and training personnel. Committed to bridging preventative medicine and disease care through holistic nutrition and wellness education. Strong problem-solving abilities, willingness to learn, and excellent communication skills. Eager to tackle new challenges, contribute to team success, and achieve positive results. Ready to advance organizational objectives with dedication and enthusiasm.

• 2017 Delta Epsilon Tau Honor Society
• 2015-2016 The Health& Wellness Network of Commerce, Bronx, NY Bronx Chapter President
• 2014-2017 MS181 –Pablo Casalls Middle School, Bronx, NY SLT/ Title I Chair- District 11
• 2009-2012 PS 41 Elementary School, Bronx, NY PTA President/SLT/ Title I Chair/ President Council Treasurer

• 2025 Certified Health Coach- HBNWC approved - Board exam -NOV 2025
• 2019 Certified Health & Wellness Life Coach, My Life Coaching Center-NY
• 2016 Memorial Sloan-Kettering Cancer Center, New York, NY Fundamentals of Supervision- Certification HR Legal training for Managers Presenting with Confidence Reframing from Conflict The Human Element
• Sept. 2001-Present New York Fire Department, Brooklyn, NY Charge Of Chemical and Laboratory. Fire Safety

• Gadal S, Boyer JA, Roy SF, Outmezguine NA, Sharma M, Li H, Fan N, Chan E, Romin Y, Barlas A, Chang Q, Pancholi P, Timaul NM, Overholtzer M, Yaeger R, Manova-Todorova K, de Stanchina E, Rosenberg MW, Rosen N. Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations That Overcome Its Feedback Inhibition of RAC1 and Migration. Cancer Res. 2025 May 2;85(9):1611-1627. doi: 10.1158/0008-5472.CAN-24-2220. PMID: 39992718; PMCID: PMC12046322.
• Mukherjee R, Pancholi P, Sharma M, Solomon H, Timaul NM, Thant C, McGriskin R, Hayatt O, Markov V, D'Allara J, Bekker S, Candelier J, Carrasco SE, de Stanchina E, Vanaja K, Rosen N. Diet induced insulin resistance is due to induction of PTEN expression. bioRxiv [Preprint]. 2025 Mar 26:2025.03.25.645201. doi: 10.1101/2025.03.25.645201. PMID: 40196497; PMCID: PMC11974787.
• Su W, Mukherjee R, Yaeger R, Son J, Xu J, Na N, Merna Timaul N, Hechtman J, Paroder V, Lin M, Mattar M, Qiu J, Chang Q, Zhao H, Zhang J, Little M, Adachi Y, Han SW, Taylor BS, Ebi H, Abdel-Wahab O, de Stanchina E, Rudin CM, Jänne PA, McCormick F, Yao Z, Rosen N. ARAF protein kinase activates RAS by antagonizing its binding to RASGAP NF1. Mol Cell. 2022 Jul 7;82(13):2443-2457.e7. doi: 10.1016/j.molcel.2022.04.034. Epub 2022 May 24. PMID: 35613620; PMCID: PMC9271631.
• Yao Z, Gao Y, Su W, Yaeger R, Tao J, Na N, Zhang Y, Chang Q, Rymar A, Tao A, Timaul NM, McGriskin R, Outmezguine NA, Zhao H, Chang Q, Qeriqi B, Barbacid M, de Stanchina E, Hyman DM, Bollag G, Rosen N.“RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling Nat Med. 2019 Feb;25(2):284-291. doi: 10.1038/s41591-018-0274-5. Epub 2018 Dec 17.
• Gao Y, Chang MT, McKay D, Na N, Zhou B, Yaeger RD, Torres NM, Muniz K, Drosten M, Barbacid M, Caponigro G3, Stuart D, Moebitz H, Solit DB, Abdel-Wahab O, Taylor BS, Yao Z, Rosen N. “Allele-specific mechanisms of activation of MEK1 mutants determine their properties.” Cancer Discovery. 2018 Feb 26. pii: CD-17-1452. doi: 10.1158/2159-8290.CD-17-1452.
• “Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.” Yao Z, Yaeger R, Rodrik-Outmezguine VS, Tao A, Torres NM, Chang MT, Drosten M, Zhao H1, Cecchi F, Hembrough T, Michels J, Baumert H, Miles L, Campbell NM, de Stanchina E, Solit DB, Barbacid M, Taylor BS, Rosen N. Nature. 2017 Aug 10;548(7666):234-238. doi: 10.1038/nature23291. Epub 2017 Aug 2.
• Yao Z, Torres NM, Tao A, Gao Y, Luo L, Li Q, de Stanchina E, Abdel-Wahab O, Solit DB, Poulikakos PI, Rosen N. “BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition.” Cancer Cell. 2015 Sep 14;28(3):370-83. doi: 10.1016/j.ccell.2015.08.001. Epub 2015 Sep 3.
• Keller, Marla J. M.D.; Madan, Rebecca P. M.D.; Shust, Gail M.D.; Carpenter, Colleen A.; Torres, N. Merna; Cho, Sylvia; Khine, Hnin M.D.; Huang, Meei-Li; Corey, Lawrence M.D.; Kim, Mimi S.C.D.; Herold, Betsy C. M.D. “Changes in the Soluble Mucosal Immune Environment during Genital Herpes Outbreaks” J Acquir Immune Defic Syndr. 2012 Jul 19
• Mesquita PM, Rastogi R, Segarra TJ, Teller RS, Torres NM, Huber AM, Kiser PF, Herold BC. “Intravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection.”J Antimicrob Chemother. 2012 Mar 3
• Charlene S. Dezzutti, Craig W. Hendrix, Jeanne M. Marrazzo, Zhenyu Pan, Lei Wang, Nicolette Louissaint, Sabah Kalyoussef, N. Merna Torres, Florian Hladik, Urvi Parikh, John Mellors, Sharon L. Hillier, Betsy C. Herold “Performance of Swabs, Lavage, and Dilutents to Quantify Biomarkers of Female Genital Tract Soluble Mucosal Mediators” PLoS ONE: Research Article, published 12 Aug 2011 10.1371/journal.pone.0023136
• Keller MJ, Madan RP, Torres NM, Fazzari MJ, Cho S, Kalyoussef S, Shust G, Mesquita PM, Louissaint N, Chen J, Cohen HW, Diament EC, Lee AC, Soto-Torres L, Hendrix CW, Herold BC. “A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel.” PLoS One. 2011 Jan 25;6(1):e16475.
• Keller MJ, Mesquita PM, Torres NM, Cho S, Shust G, Madan RP, Cohen HW, Petrie J, Ford T, Soto-Torres L, Profy AT, Herold BC. “Postcoital bioavailability and antiviral activity of 0.5% PRO 2000 gel: implications for future microbicide clinical trials.” PLoS One. 2010 Jan 22; 5(1): e8781.
• Chiosis G, Timaul NM, Lucas B, Munster PN, Zheng FF, Sepp-Lorenzino L, Rosen N. “A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells.” Chem. Biol. 2001 Mar;8(3): 289-99.
• Sepp-Lorenzino L, Tjaden G, Moasser MM, Timaul N, Ma Z, Kohl NE, Gibbs JB, Oliff A, Rosen N, Scher HI.
• “Farnesyl: protein transferase inhibitors as potential agents for the management of human prostate cancer.” Prostate Cancer Prostatic Dis. 2001; 4 (1): 33-43.
• Sepp-Lorenzino L, Balog A, Su DS, Meng D, Timaul N, Scher HI, Danishefsky SJ, Rosen N. “The microtubule-stabilizing agents epothilones A and B and their desoxy-derivatives induce mitotic arrest and apoptosis in human prostate cancer cells.” Prostate Cancer Prostatic Dis. 1999 Jan; 2 (1): 41-52.
• Lebwohl DE, Muise-Helmericks R, Sepp-Lorenzino L, Serve S, Timaul M, Bol R, Borgen P, Rosen N. “A truncated cyclin D1 gene encodes a stable mRNA in a human breast cancer cell line.” Oncogene. 1994 Jul; 9(7): 1925-9.

• NOTE: Published under married name: Torres Several acknowledgements for technical assistant on various laboratory techniques.